PT2240170T - Métodos e composições para o tratamento de hemorragia subaracnóidea aneurismática coronária e arterial - Google Patents

Métodos e composições para o tratamento de hemorragia subaracnóidea aneurismática coronária e arterial

Info

Publication number
PT2240170T
PT2240170T PT09708687T PT09708687T PT2240170T PT 2240170 T PT2240170 T PT 2240170T PT 09708687 T PT09708687 T PT 09708687T PT 09708687 T PT09708687 T PT 09708687T PT 2240170 T PT2240170 T PT 2240170T
Authority
PT
Portugal
Prior art keywords
coronary
compositions
treatment
methods
subarachnoid hemorrhage
Prior art date
Application number
PT09708687T
Other languages
English (en)
Inventor
L Summar Marshall
E Barr Frederick
Carleton Thompson Reid
Original Assignee
Univ Vanderbilt
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Vanderbilt filed Critical Univ Vanderbilt
Publication of PT2240170T publication Critical patent/PT2240170T/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
    • A61K31/198—Alpha-aminoacids, e.g. alanine, edetic acids [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
PT09708687T 2008-01-31 2009-02-02 Métodos e composições para o tratamento de hemorragia subaracnóidea aneurismática coronária e arterial PT2240170T (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US2517008P 2008-01-31 2008-01-31

Publications (1)

Publication Number Publication Date
PT2240170T true PT2240170T (pt) 2019-06-24

Family

ID=40932329

Family Applications (1)

Application Number Title Priority Date Filing Date
PT09708687T PT2240170T (pt) 2008-01-31 2009-02-02 Métodos e composições para o tratamento de hemorragia subaracnóidea aneurismática coronária e arterial

Country Status (16)

Country Link
US (3) US20090197964A1 (pt)
EP (1) EP2240170B1 (pt)
JP (2) JP5623916B2 (pt)
KR (2) KR20100135728A (pt)
CN (2) CN102369006A (pt)
AU (2) AU2009212693B2 (pt)
BR (1) BRPI0906608A2 (pt)
CA (1) CA2715260C (pt)
DK (1) DK2240170T3 (pt)
ES (1) ES2732810T3 (pt)
HU (1) HUE045571T2 (pt)
PL (1) PL2240170T3 (pt)
PT (1) PT2240170T (pt)
RU (1) RU2528097C2 (pt)
SG (1) SG196863A1 (pt)
WO (1) WO2009099999A2 (pt)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9486429B2 (en) * 1999-06-01 2016-11-08 Vanderbilt University Therapeutic methods employing nitric oxide precursors
US6346382B1 (en) 1999-06-01 2002-02-12 Vanderbilt University Human carbamyl phosphate synthetase I polymorphism and diagnostic methods related thereto
AU2006249323B2 (en) 2005-05-27 2012-08-30 The University Of North Carolina At Chapel Hill Nitric oxide-releasing particles for nitric oxide therapeutics and biomedical applications
JP5623916B2 (ja) 2008-01-31 2014-11-12 バンダービルト・ユニバーシティＶａｎｄｅｒｂｉｌｔ Ｕｎｉｖｅｒｓｉｔｙ 動脈瘤性くも膜下出血及び血管痙攣に対する医薬組成物
CN104083352A (zh) * 2008-01-31 2014-10-08 范德比尔特大学 对于肺部病症的治疗
CN102711729B (zh) 2009-08-21 2015-04-01 诺万公司 局部用凝胶
DK2467173T3 (da) 2009-08-21 2019-07-29 Novan Inc Sårbandager, fremgangsmåder til anvendelse heraf og fremgangsmåder til dannelse deraf
US8591876B2 (en) 2010-12-15 2013-11-26 Novan, Inc. Methods of decreasing sebum production in the skin
EP2681286B1 (en) 2011-02-28 2018-08-15 Novan, Inc. Nitric oxide-releasing s-nitrosothiol-modified silica particles and methods of making the same
MX2017015664A (es) 2015-06-29 2018-04-18 Univ Vanderbilt Administracion intravenosa de citrulina durante cirugia.

Family Cites Families (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA716628B (en) 1970-10-15 1972-06-28 Richardson Merrell Spa Composition and method for treatment of hepatic disease and mental fatigue
US4196265A (en) * 1977-06-15 1980-04-01 The Wistar Institute Method of producing antibodies
US4458066A (en) * 1980-02-29 1984-07-03 University Patents, Inc. Process for preparing polynucleotides
NL8102724A (nl) 1980-07-11 1982-02-01 Stamicarbon Werkwijze voor de bereiding van copolymeren van etheen met tenminste een ander 1-alkeen.
US4554101A (en) * 1981-01-09 1985-11-19 New York Blood Center, Inc. Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity
US4769331A (en) * 1981-09-16 1988-09-06 University Patents, Inc. Recombinant methods and materials
US4736866B1 (en) * 1984-06-22 1988-04-12 Transgenic non-human mammals
US4965188A (en) * 1986-08-22 1990-10-23 Cetus Corporation Process for amplifying, detecting, and/or cloning nucleic acid sequences using a thermostable enzyme
US4683195A (en) * 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4683202A (en) * 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US5573933A (en) * 1987-04-14 1996-11-12 Luminis Pty, Ltd. Transgenic pigs
US4996236A (en) * 1988-06-22 1991-02-26 Takeda Chemical Industries, Ltd. Therapeutic composition for hepatic encephalopathy
US5162215A (en) * 1988-09-22 1992-11-10 Amgen Inc. Method of gene transfer into chickens and other avian species
US5399346A (en) * 1989-06-14 1995-03-21 The United States Of America As Represented By The Department Of Health And Human Services Gene therapy
US5286634A (en) * 1989-09-28 1994-02-15 Stadler Joan K Synergistic method for host cell transformation
US5633076A (en) * 1989-12-01 1997-05-27 Pharming Bv Method of producing a transgenic bovine or transgenic bovine embryo
EP0441119A3 (en) * 1990-01-09 1992-10-14 Richard D. Levere The use of l-arginine in the treatment of hypertension and other vascular disorders
US5279833A (en) * 1990-04-04 1994-01-18 Yale University Liposomal transfection of nucleic acids into animal cells
US5614396A (en) * 1990-06-14 1997-03-25 Baylor College Of Medicine Methods for the genetic modification of endogenous genes in animal cells by homologous recombination
US5489742A (en) * 1990-10-23 1996-02-06 Board Of Regents, The University Of Texas System Transgenic rats and animal models of inflammatory disease
DE69121903T2 (de) * 1990-12-04 1997-04-10 Univ Texas Methoden und zusammensetzungen zur unterdrückung der zelltransformation durch neu
US5641484A (en) * 1990-12-04 1997-06-24 Board Of Regents, The University Of Texas System Methods for the suppression of neu mediated tumors by adenoviral E1A and SV40 large T antigen
US5643567A (en) * 1990-12-04 1997-07-01 Board Of Regents, The University Of Texas System Methods for the suppression of neu mediated tumors by adenoviral E1A and SV40 large T antigen
ES2288660T5 (es) * 1990-12-05 2015-05-29 The General Hospital Corporation Uso de NO para tratar la hipertensión pulmonar persistente del recién nacido
US5550316A (en) * 1991-01-02 1996-08-27 Fox Chase Cancer Center Transgenic animal model system for human cutaneous melanoma
US5550024A (en) * 1991-04-19 1996-08-27 Biotechnology Research & Development Corporation Genetic markers for pig litter size
US5286739A (en) * 1991-09-27 1994-02-15 Board Of Regents, University Of Texas System Parenteral formulations for the inhibition of systemic hypotension associated with nitric oxide production or endothelial derived relaxing factor
US5374651A (en) 1991-09-27 1994-12-20 Board Of Regents, The University Of Texas System Methods and compositions for the treatment of hypotension with arginine free essential and essential amino acids and arginine derivatives
US5334380A (en) 1991-09-27 1994-08-02 Board Of Regents, The University Of Texas System Anti-endotoxin, interleukin-1 receptor antagonist and anti-tumor necrosis factor antibody with arginine-free formulations for the treatment of hypotension
US5385940A (en) 1992-11-05 1995-01-31 The General Hospital Corporation Treatment of stroke with nitric-oxide releasing compounds
AU6232794A (en) 1993-01-29 1994-08-15 Brigham And Women's Hospital The use of nitric oxide-delivering compounds for the treatment or prevention of alcoholic liver injury
US5891459A (en) * 1993-06-11 1999-04-06 The Board Of Trustees Of The Leland Stanford Junior University Enhancement of vascular function by modulation of endogenous nitric oxide production or activity
US5646008A (en) * 1993-06-22 1997-07-08 The Regent Of The University Of Michigan Vertebrate apoptosis gene: compositions and methods
US5625125A (en) * 1994-08-09 1997-04-29 Dnx Biotherapeutics Phospholipase A2 expressing transgenic animals
US5543430A (en) * 1994-10-05 1996-08-06 Kaesemeyer; W. H. Method and formulation of stimulating nitric oxide synthesis
US5648061A (en) * 1995-05-24 1997-07-15 Thomas Jefferson University In vivo and in vitro model of cutaneous photoaging
US6331543B1 (en) 1996-11-01 2001-12-18 Nitromed, Inc. Nitrosated and nitrosylated phosphodiesterase inhibitors, compositions and methods of use
US5874471A (en) * 1997-02-27 1999-02-23 Waugh; William Howard Orthomolecular medical use of L-citrulline for vasoprotection, relaxative smooth muscle tone and cell protection
US6028107A (en) * 1997-02-27 2000-02-22 Waugh; William Howard Orthomolecular medical use of L-citrulline for vasoprotection, relaxative smooth muscle tone and cell protection
US6796966B2 (en) 1997-10-15 2004-09-28 Jeffrey E. Thomas Apparatus, and kits for preventing of alleviating vasoconstriction or vasospasm in a mammal
WO1999018949A1 (en) * 1997-10-15 1999-04-22 Thomas Jefferson University Nitric oxide donor compositions, methods, apparatus, and kits for preventing or alleviating vasoconstriction or vasospasm in a mammal
US20010056068A1 (en) * 1998-03-04 2001-12-27 Kristof Chwalisz Method of treatment and prevention of nitric oxide deficiency-related disorders with citrulline and citrulline derivatives
US20020068365A1 (en) 1998-07-28 2002-06-06 Eric H. Kuhrts Controlled release nitric oxide producing agents
US6346382B1 (en) * 1999-06-01 2002-02-12 Vanderbilt University Human carbamyl phosphate synthetase I polymorphism and diagnostic methods related thereto
US9486429B2 (en) 1999-06-01 2016-11-08 Vanderbilt University Therapeutic methods employing nitric oxide precursors
US6182295B1 (en) * 1999-06-14 2001-02-06 Kevin Sciglia Hat
JP3506114B2 (ja) 2000-01-25 2004-03-15 株式会社ニコン モニタ装置及びこのモニタ装置を具えた研磨装置及び研磨方法
RU2202269C2 (ru) * 2001-02-14 2003-04-20 Жильвинас Закарявичюс Способ прогнозирования исхода хирургического лечения у больных среднего возраста в остром периоде внутричерепных кровоизлияний аневризматической природы
US6689810B2 (en) * 2001-08-21 2004-02-10 Cellular Sciences, Inc. Method for treating pulmonary disease states in mammals by altering indigenous in vivo levels of nitric oxide
EP1448600A4 (en) * 2001-09-07 2004-12-22 Bristol Myers Squibb Co POLYNUCLEOTIDE ENCODING A NOVEL HUMAN G PROTEIN-RELATED RECEPTOR, HGPRMBY39
US20030134332A1 (en) * 2001-11-28 2003-07-17 Boykin Joseph V. Diagnosis of endothelial dysfunction by nitric oxide bioactivity index
US6899140B2 (en) 2002-08-12 2005-05-31 Wellstream International Limited Flexible pipe and method of manufacturing same using metal reinforced tape
PT1841458E (pt) * 2005-01-06 2012-04-10 Discovery Lab Inc Regime de tratamento com surfactante para tratar ou prevenir displasia broncopulmonar
CA2632238A1 (en) * 2005-12-01 2007-06-07 Nps Pharmaceuticals, Inc. A biomarker of improved intestinal function
CN104083352A (zh) * 2008-01-31 2014-10-08 范德比尔特大学 对于肺部病症的治疗
JP5623916B2 (ja) * 2008-01-31 2014-11-12 バンダービルト・ユニバーシティＶａｎｄｅｒｂｉｌｔ Ｕｎｉｖｅｒｓｉｔｙ 動脈瘤性くも膜下出血及び血管痙攣に対する医薬組成物
US20090291066A1 (en) 2008-05-22 2009-11-26 Apostolos Pappas composition and method of treating facial skin defect

Also Published As

Publication number Publication date
AU2009212693A1 (en) 2009-08-13
RU2010132580A (ru) 2012-03-10
SG196863A1 (en) 2014-02-13
AU2009212693B2 (en) 2014-05-01
US9943494B2 (en) 2018-04-17
KR20100135728A (ko) 2010-12-27
WO2009099999A2 (en) 2009-08-13
DK2240170T3 (da) 2019-07-15
US20090197964A1 (en) 2009-08-06
HUE045571T2 (hu) 2020-01-28
RU2528097C2 (ru) 2014-09-10
PL2240170T3 (pl) 2019-11-29
EP2240170B1 (en) 2019-05-22
EP2240170A2 (en) 2010-10-20
CN105106186A (zh) 2015-12-02
JP2011519821A (ja) 2011-07-14
CA2715260C (en) 2017-07-04
JP2015017119A (ja) 2015-01-29
KR101932831B1 (ko) 2018-12-27
EP2240170A4 (en) 2014-10-29
BRPI0906608A2 (pt) 2015-07-14
CN102369006A (zh) 2012-03-07
ES2732810T3 (es) 2019-11-26
US20120088835A1 (en) 2012-04-12
AU2014204508A1 (en) 2014-08-07
US10500181B2 (en) 2019-12-10
JP5623916B2 (ja) 2014-11-12
AU2014204508B2 (en) 2016-07-14
US20180360787A1 (en) 2018-12-20
KR20170005497A (ko) 2017-01-13
CA2715260A1 (en) 2009-08-13
WO2009099999A3 (en) 2013-11-28
JP6042392B2 (ja) 2016-12-14

Similar Documents

Publication Publication Date Title
HUE045571T2 (hu) Koronáriás és artériás aneurizmás szubarachnoideális vérzés kezelésére szolgáló eljárások és készítmények
EP2313146A4 (en) DEVICES FOR TREATING VASCULAR ANEVRYSM
EP2361089A4 (en) COMPOSITIONS AND METHODS FOR THE TREATMENT OF ALTERED FUNCTION OF -SYNUCLEINE
EP2262474A4 (en) METHOD AND COMPOSITIONS FOR WOUND HEALING
IL202095A0 (en) Vascular stent
EP2157937A4 (en) METHODS AND DEVICES FOR TREATING VASCULAR DEFECTS
EP2271301A4 (en) METHODS AND COMPOSITIONS FOR THE DELIVERY OF AGENTS
AU320819S (en) Surgical spatula
IL194975A0 (en) Composition and methods for treatment of congestive heart failure
ZA200900388B (en) Compositions and methods for the treatment of mucositis
HK1159498A1 (en) Methods and compositions for the treatment of cancer
ZA201006625B (en) In-shower and bath compositions
EP2124985A4 (en) METHOD AND COMPOSITIONS FOR TREATING NERVOUS ELEMENTS
HRP20190437T1 (hr) Sredstva za ometanje vaskularizacije aktivirana mmp-om
EP2331123A4 (en) COMPOSITIONS AND METHODS FOR TREATING HEPATITIS C
IL210097A0 (en) Compositions and methods for treating unfluenza
EP2340027A4 (en) METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER
ZA200900140B (en) Methods and compositions for treating biofilms
EP2341936A4 (en) METHOD FOR TREATING OR PREVENTING IL-1ß-CONTAINED ILLNESSES
EP2301486A4 (en) VASCULAR STENT
EP2304049A4 (en) METHOD FOR TREATING VASCULAR COMPLICATIONS
EP2285398A4 (en) METHOD AND COMPOSITIONS FOR TREATING ADIPOSITAS
EP2134862A4 (en) COMPOSITIONS AND METHODS FOR THE DIAGNOSIS AND TREATMENT OF DIABETIC MICROVASCULAR COMPLICATIONS
EP2411020A4 (en) COMPOSITIONS AND METHODS FOR THE TREATMENT OF HEMORRHAGE
EP2384323A4 (en) INTRAVASCULAR CONTRAST AGENTS